A phase 2 trial of tolebrutinib, a Bruton's tyrosine kinase inhibitor, for chronic active lesions in multiple sclerosis

Authors
Category Primary study
Conference10th Congress of the European Academy of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: a39e22b00a2221fc352ad036ffa66800a16f99f1
First added on: Jan 07, 2026